Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica.
In this work, we describe the clinical and instrumental results of our experience, the first reported in the literature, of the administration of teriparatide to treat severe osteoporosis secondary to epidermolysis bullosa. Already after 2 months of therapy, the patient, a 20-year-old affected by a recessive form of epidermolysis bullosa dystrophica, had less pain and a functional recovery resulting in an improved autonomy; a satisfactory increase in the densitometric values was documented.
Moretti
L
L
Orthopedic and Traumatology Unit, Department of Clinical Methodology and Surgical Techniques, University of Bari, Bari, Italy.
Notarnicola
A
A
Panella
A
A
Garofalo
L
L
Garofalo
R
R
Santamato
A
A
Moretti
B
B
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016108:Epidermolysis Bullosa Dystrophica / Q000150:complications; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000534:rehabilitation; D019379:Teriparatide / Q000627:therapeutic use*; D055815:Young Adult
D050071:Bone Density Conservation Agents; D019379:Teriparatide
Br J Dermatol. 1999 Nov;141(5):934-5
10583187
Int J Dermatol. 2007 Aug;46(8):795-800
17651159
Clin Orthop Relat Res. 2004 Aug;(425):126-34
15292797
J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1078-83
2273105
Br J Dermatol. 1998 Apr;138(4):661-6
9640376
Arch Dermatol. 2009 Jan;145(1):95-6
19153360
Acta Dermatovenerol Croat. 2009;17(2):147-8
19595275
Paediatr Anaesth. 2009 Jul;19(7):706-7
19638122
Br J Dermatol. 2006 May;154(5):959-62
16634901